Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2000-12-22
2009-10-27
Liu, Sue (Department: 1639)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S317000, C530S326000, C436S506000, C436S507000, C436S509000
Reexamination Certificate
active
07608681
ABSTRACT:
Peptide ligands having affinity for IgG or for serum albumin are disclosed. Also disclosed are hybrid molecules comprising a peptide ligand domain and an active domain. The active domain may comprise any molecule having utility as a therapeutic or diagnostic agent. The hybrid molecules of the invention may be prepared using any of a number techniques including production in and purification from recombinant organisms transformed or transfected with an isolated nucleic acid encoding the hybrid molecule, or by chemical synthesis of the hybrid. The hybrid molecules have utility as agents to alter the elimination half-times of active domain molecules. Elimination half-time is altered by generating a hybrid molecule of the present invention wherein the peptide ligand has binding affinity for a plasma protein. In a preferred embodiment, a bioactive molecule having a short elimination half-time is incorporated as or into an active domain of the hybrid molecules of the invention, and the binding affinity of the peptide ligand domain prolongs the elimination half-time of the hybrid as compared to that of the bioactive molecule.
REFERENCES:
patent: 3561444 (1971-02-01), Boucher
patent: 3703173 (1972-11-01), Dixon
patent: 3842067 (1974-10-01), Sarantakis
patent: 3862925 (1975-01-01), Sarantakis
patent: 3972859 (1976-08-01), Fujino et al.
patent: 4105603 (1978-08-01), Vale, Jr. et al.
patent: 4399216 (1983-08-01), Axel et al.
patent: 4624251 (1986-11-01), Miller
patent: 4635627 (1987-01-01), Gam
patent: 4970198 (1990-11-01), Lee et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5079233 (1992-01-01), Lee et al.
patent: 5135736 (1992-08-01), Anderson
patent: 5585089 (1996-12-01), Queen et al.
patent: 5606040 (1997-02-01), McGahren et al.
patent: 5679777 (1997-10-01), Anderson et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5739116 (1998-04-01), Hamann et al.
patent: 5767237 (1998-06-01), Sakakibara et al.
patent: 5767285 (1998-06-01), Hamann et al.
patent: 5773001 (1998-06-01), Hamann et al.
patent: 5780054 (1998-07-01), Tardi et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6124431 (2000-09-01), Sakakibara et al.
patent: 6387371 (2002-05-01), Hudziak et al.
patent: 6632979 (2003-10-01), Erickson et al.
patent: 2002/0032315 (2002-03-01), Baca et al.
patent: 2003/0069395 (2003-04-01), Sato et al.
patent: 2003/0228663 (2003-12-01), Lowman et al.
patent: 2004/0001827 (2004-01-01), Dennis
patent: 2004/0018194 (2004-01-01), Francisco et al.
patent: 2004/0032828 (2004-02-01), Satt
patent: 2005/0089932 (2005-04-01), Kolkma et al.
patent: 2005/0287153 (2005-12-01), Dennis
patent: 2006/0228364 (2006-10-01), Dennis et al.
patent: 0486525 (1994-06-01), None
patent: 486525 (1994-06-01), None
patent: 602290 (1999-08-01), None
patent: WO 88/07543 (1988-10-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 90/01940 (1990-03-01), None
patent: WO 91/01743 (1991-02-01), None
patent: WO 94/18318 (1994-08-01), None
patent: WO 96/40921 (1996-12-01), None
patent: WO 98/22141 (1998-05-01), None
patent: WO 01/45746 (2001-06-01), None
patent: WO 01/79444 (2001-10-01), None
patent: WO 01/79480 (2001-10-01), None
patent: WO 03/031464 (2003-04-01), None
patent: WO 03/043583 (2003-05-01), None
patent: WO 2004/032828 (2004-04-01), None
Nef et al. EMBO Journal. vol. 7(3): 595-601; 1988.
GenBank accession No. P09480; earliest version date 1993; downloaded Sep. 14, 2008.
Abrahmsen et al., “Analysis of Signals for Secretion in the Staphylococcal Protein A Gene.”EMBO Journal4:3901-3906 (1985).
Adams and Schier., “Generating Improved Single-Chain Fv Molecules for Tumor Targeting.”J. Immunol. Methods231:249-260 (1999).
Adams., “Improving the Tumor Specificity and Retention of Antibody-Based Molecules.”In Vivo12:11-22 (1998).
Affleck and Embleton., “Monoclonal Antibody Targeting of Methotrexate (MTX) Against MTX-Resistant Tumor Cell Lines.”Br. J. Cancer65:838-844 (Jun. 1992).
Aida and Pabst., “Removal of Endotoxin from Protein Solutions by Phase Separation Using Triton X-114.”J. Immunol. Methods132:191-195 (1990).
Arap et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model”Science279:377-380 (1998).
Ashkenazi and Chamow., “Immunoadhesins as Research Tools and Therapeutic Agents.”Curr. Op. Immunol.9:195-200 (1997).
Batrla et al., “CD40-Expressing Carcinoma Cells Induce Down-Regulation of CD40 Ligand (CD154) and Impair T-Cell Functions.”Cancer Research62:2052-2057 (Apr. 2002).
Burger et al., “Pre-Clinical Evaluation of a Methotrexate-Albumin Conjugate (MTX-HSA) in Human Tumor Xenografts In vivo.”Int. J. Cancer.92:718-724 (2001).
Carter, “American Chemical Society Symposium Series No. 427”Protein Purification: From Molecular Mechanisms to Large-Scale Processes., Ladisch et al., Eds., Chapter 13, pp. 181-193 (1990).
Clackson and Wells, “In Vitro Selection from Protein and Peptide Libraries.”Trends Biotechnol.12:173-184 (1994).
Clark et al., “Long-Acting Growth Hormones Produced by Conjugation with Polyethylene Glycol.”Journal of Biological Chemistry271(36) :21969-21977 (Sep. 6, 1996).
Cunningham et al., “Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor”EMBO Journal13(11) :2508-2515 (1994).
Cwirla et al., “Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine.”Science276(5319) :1696-1699 (1997).
Dennis and Lazarus, “Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa; II. Potent and Specific Inhibitors by Competitive Phage Selection”Journal of Biological Chemistry269(35):22137-22144 (1994).
Dennis et al., “Peptide Exosite Inhibitors of Factor VIIa as Anticoagulants.”Nature404:465-470 (Mar. 2000).
Dennis et al., “Selection and Characterization of a New Class of Peptide Exosite Inhibitors of Coagulation Factor VIIIa.”Biochemistry40:9513-9521 (2001).
Fendley et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product.”Cancer Research50:1550-1558 (Mar. 1990).
Ferrari et al., “Mutations of CD40 Gene Cause an Autosomal Recessive Form of Immunodeficiency with Hyper IgM.”Proc. Natl. Acad. Sci. USA98(22) :12614-12619 (Oct. 2001).
Goldberg et al., “The Biodegradation of Albumin Microspheres Used for Regional Chemotherapy in Patients with Colorectal Liver Metastases.”Nucl. Med. Commun.12:57-63 (Jan. 1991).
Goodman and Gilman, Eds., “Time Course of Drug Effect: Pharmacokinetic Principles.”The Pharmaceutical Basis of Therapeutics., 6th edition, NY:MacMillan Publishing Co., Chapter 1, pp. 21-25 (1980).
Gupta and Hung., “Albumin Microspheres II: Applications in Drug Delivery.”J. Microencapsul.6(4) :463-472 (Oct.-Dec. 1989).
Houghten., “General Method for the Rapid Solid-Phase Synthesis of Large Numbers of Peptides: Specificity of Antigen-Antibody Interaction at the Level of Individual Amino Acids.”Proc. Natl. Sci. USA82:5131-5135 (Aug. 1985).
Keyt et al., “A Faster-Acting and More Potent Form of Tissue Plasminogen Activator.”Proc. Natl. Acad. Sci. USA91:3670-3674 (1994).
Kiessling et al., “Magnetic Resonance Imagine of Nude Mice with Heterotransplanted High-Grade Squamous Cell Carcinomas: Use of a Low-Loaded, Covalently bound Gd-Hsa Conjugate as Contrast Agent with High Tumor Affinity.”Invest. Radiol.37:193-198 (Apr. 2002).
Kunkel et al., “Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection”Methods in Enzymology154:367-382 (1987).
Kurtzhals et al., “Albumin Binding of Insulins Acylated with Fatty Acids: Characterization of the Lignad-Protein Interaction and Correlation Between Binding Affinity and Timing of the Insulin Effect In Vivo.”Biochemi
DeLano Warren L.
Dennis Mark S.
Lowman Henry B.
Dreger Ginger
Genentech Inc.
Goodwin & Procter LLP
Liu Sue
Shin Elinor
LandOfFree
Methods and compositions for prolonging elimination... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for prolonging elimination..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for prolonging elimination... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4099540